Merus BV (MRUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Merus BV (MRUS) has a cash flow conversion efficiency ratio of -0.128x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-84.92 Million) by net assets ($661.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MRUS market cap for the company's overall valuation and market capitalisation.
Merus BV - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Merus BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Merus BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merus BV ranked by their cash flow conversion efficiency. See MRUS cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KakaoBank Corp
KO:323410
|
0.190x |
|
Korea Investment Holdings Co
KO:071050
|
0.100x |
|
Molson Coors Brewing Co Class B
NYSE:TAP
|
0.079x |
|
Inventec Corp
TW:2356
|
0.239x |
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
0.026x |
|
Sprouts Farmers Market LLC
NASDAQ:SFM
|
0.089x |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
0.117x |
|
Fluor Corporation
NYSE:FLR
|
0.039x |
Annual Cash Flow Conversion Efficiency for Merus BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of Merus BV from 2013 to 2024. View MRUS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $650.36 Million | $-185.84 Million | -0.286x | +28.40% |
| 2023-12-31 | $356.34 Million | $-142.21 Million | -0.399x | +34.23% |
| 2022-12-31 | $247.06 Million | $-149.90 Million | -0.607x | -221.76% |
| 2021-12-31 | $316.20 Million | $-59.63 Million | -0.189x | +75.87% |
| 2020-12-31 | $102.26 Million | $-79.90 Million | -0.781x | -62.71% |
| 2019-12-31 | $131.30 Million | $-63.05 Million | -0.480x | -8.93% |
| 2018-12-31 | $105.09 Million | $-46.33 Million | -0.441x | +43.58% |
| 2017-12-31 | $57.45 Million | $-44.88 Million | -0.781x | -3.32% |
| 2016-12-31 | $35.79 Million | $-27.06 Million | -0.756x | +7.08% |
| 2015-12-31 | $30.94 Million | $-25.18 Million | -0.814x | -119.85% |
| 2014-12-31 | $-4.33 Million | $-17.74 Million | 4.099x | +551.01% |
| 2013-12-31 | $10.58 Million | $-9.62 Million | -0.909x | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more